Consensus ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Real-time Estimate Cboe BZX Other stock markets 11:14:45 2024-05-17 am EDT			5-day change	1st Jan Change
14.54 ^USD	-0.82%		-10.43%	-2.48%

May. 09	ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 08	Alx Oncology Holdings Insider Sold Shares Worth $318,334, According to a Recent SEC Filing	MT

Evolution of the average Target Price on ALX Oncology Holdings Inc.

Price target over the last 5 years

History of analyst recommendation changes

5de14cdc0c552f3ac2397f27b2.-TOBWVFv5ulGvlINw8mMeoYQqMu4V56Di_G_DNWVIJ8.mEfFGz4hraoQ5x1l8q7aSPNjx4H0CK3c77DSdazlWdjIB94aN1y1jweIMQ~ffca5de74189f89b1d61dc61e095e209

Analyst Recommendations on ALX Oncology Holdings Inc.

Alx Oncology Holdings Insider Sold Shares Worth $318,334, According to a Recent SEC Filing	May. 08	MT
Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing	Apr. 18	MT
UBS Adjusts ALX Oncology Price Target to $25 From $27, Maintains Buy Rating	Mar. 13	MT
H.C. Wainwright Adjusts Price Target on ALX Oncology to $20 From $17.50, Keeps Buy Rating	Mar. 11	MT
Piper Sandler Adjusts Price Target on ALX Oncology Holdings to $21 From $11, Maintains Overweight Rating	Mar. 08	MT
Stifel Downgrades ALX Oncology Holdings to Hold From Buy, Adjusts Price Target to $14 From $10	Mar. 08	MT
Jefferies Upgrades ALX Oncology to Buy From Hold, Adjusts Price Target to $18 From $8	Dec. 08	MT
Stifel Trims ALX Oncology Holdings' Price Target to $10 From $11, Maintains Buy Rating	Nov. 14	MT
Piper Sandler Raises Price Target on ALX Oncology to $11 From $8, Maintains Overweight Rating	23-10-11	MT
UBS Adjusts ALX Oncology Price Target to $27 From $29, Maintains Buy Rating	23-10-04	MT
Cantor Fitzgerald Raises Price Target on ALX Oncology to $23 From $18, Maintains Overweight Rating	23-10-04	MT
Cantor Fitzgerald Cuts Price Target on ALX Oncology Holdings to $18 From $22, Maintains Overweight Rating	23-08-14	MT
HC Wainwright Adjusts ALX Oncology Price Target to $16 From $30, Maintains Buy Rating	23-08-11	MT
UBS Adjusts ALX Oncology's Price Target to $29 From $31, Maintains Buy Rating	23-03-15	MT
Credit Suisse Lowers ALX Oncology Holdings' Price Target to $34 From $38, Keeps Outperform Rating	23-03-10	MT
HC Wainwright Adjusts ALX Oncology Price Target to $30 From $65, Maintains Buy Rating	23-03-10	MT
HC Wainwright Lowers Price Target on ALX Oncology Holdings to $65 From $80, Maintains Buy Rating	22-11-09	MT
UBS Adjusts ALX Oncology Price Target to $31 From $37, Maintains Buy Rating	22-08-26	MT
Cantor Fitzgerald Adjusts ALX Oncology Holdings' Price Target to $32 from $60, Maintains Overweight Rating	22-08-09	MT
Credit Suisse Lowers ALX Oncology Holdings' PT to $38 from $43, Notes Increased Discount Rate to Reflect Greater Uncertainty on Interest Rate/Inflation; Keeps Outperform Rating	22-08-09	MT
Stifel Adjusts Price Target on ALX Oncology Holdings to $16 From $35, Reiterates Buy Rating	22-06-06	MT
Piper Sandler Adjusts Price Target on ALX Oncology Holdings to $48 From $70, Reiterates Overweight Rating	22-05-19	MT
Cantor Fitzgerald Adjusts Price Target for ALX Oncology to $60 From $103, Maintains Overweight Rating	22-03-14	MT
Stifel Adjusts ALX Oncology Holdings' Price Target to $36 from $60, Maintains Buy Rating	22-03-01	MT
HC Wainwright Adjusts Price Target on ALX Oncology Holdings to $80 From $100, Reiterates Buy Rating	22-03-01	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.66 USD

Average target price

21 USD

Spread / Average Target

+43.25%

High Price Target

25 USD

Spread / Highest target

+70.53%

Low Price Target

14 USD

Spread / Lowest Target

-4.50%

Consensus detail

Consensus revision (last 18 months)

Analysts covering ALX Oncology Holdings Inc.

UBS
HC Wainwright
Piper Sandler
Stifel Nicolaus
Jefferies & Co.
Cantor Fitzgerald
Credit Suisse

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar